JP2015526391A - 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン - Google Patents

抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン Download PDF

Info

Publication number
JP2015526391A
JP2015526391A JP2015517382A JP2015517382A JP2015526391A JP 2015526391 A JP2015526391 A JP 2015526391A JP 2015517382 A JP2015517382 A JP 2015517382A JP 2015517382 A JP2015517382 A JP 2015517382A JP 2015526391 A JP2015526391 A JP 2015526391A
Authority
JP
Japan
Prior art keywords
ifn
type
patient
antibody
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526391A5 (https=
Inventor
ヒッグズ，ブランドン
ヤオ，イホン
ワン，ビン
ロスコス，ローリン
チャン，リンダ
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015526391(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2015526391A publication Critical patent/JP2015526391A/ja
Publication of JP2015526391A5 publication Critical patent/JP2015526391A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Pure & Applied Mathematics (AREA)
JP2015517382A 2012-06-13 2013-06-12 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン Pending JP2015526391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
US61/659,138 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017231307A Division JP2018065845A (ja) 2012-06-13 2017-12-01 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン

Publications (2)

Publication Number Publication Date
JP2015526391A true JP2015526391A (ja) 2015-09-10
JP2015526391A5 JP2015526391A5 (https=) 2016-07-14

Family

ID=49758685

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015517382A Pending JP2015526391A (ja) 2012-06-13 2013-06-12 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2017231307A Pending JP2018065845A (ja) 2012-06-13 2017-12-01 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2019033979A Active JP6814238B2 (ja) 2012-06-13 2019-02-27 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2020174325A Ceased JP2021042208A (ja) 2012-06-13 2020-10-16 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2021112707A Active JP7123225B2 (ja) 2012-06-13 2021-07-07 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017231307A Pending JP2018065845A (ja) 2012-06-13 2017-12-01 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2019033979A Active JP6814238B2 (ja) 2012-06-13 2019-02-27 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2020174325A Ceased JP2021042208A (ja) 2012-06-13 2020-10-16 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2021112707A Active JP7123225B2 (ja) 2012-06-13 2021-07-07 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン

Country Status (9)

Country Link
US (1) US9493570B2 (https=)
EP (1) EP2861621A4 (https=)
JP (5) JP2015526391A (https=)
KR (3) KR102320059B1 (https=)
CN (3) CN104603152A (https=)
AU (3) AU2013274389A1 (https=)
CA (1) CA2876636C (https=)
HK (1) HK1209758A1 (https=)
WO (1) WO2013188494A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511227A (ja) * 2021-04-23 2024-03-12 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024518735A (ja) * 2021-04-23 2024-05-02 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
CN108699608A (zh) * 2015-10-09 2018-10-23 基因前沿公司 用于预测和诊断人巨细胞病毒(hCMV)先天性传播的方法和试剂盒
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
WO2018172957A1 (en) 2017-03-21 2018-09-27 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
US11139051B2 (en) * 2018-10-02 2021-10-05 Origent Data Sciences, Inc. Systems and methods for designing clinical trials
JP2022512796A (ja) 2018-10-26 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド Ｉ型インターフェロンシグネチャー及び使用方法
CN115925950A (zh) * 2019-01-31 2023-04-07 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514150A (ja) * 2008-02-08 2011-05-06 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101678116A (zh) 2006-05-11 2010-03-24 根特大学 通过唾液酸粘附素靶向巨噬细胞
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
EP2712930A3 (en) 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
NZ585064A (en) * 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514150A (ja) * 2008-02-08 2011-05-06 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, D.D. ET AL., J CLIN PHARMACOL, vol. 49, no. 9, JPN6016033501, 2009, pages 1012 - 24, ISSN: 0003608096 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511227A (ja) * 2021-04-23 2024-03-12 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024518735A (ja) * 2021-04-23 2024-05-02 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療
JP7484027B2 (ja) 2021-04-23 2024-05-15 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP7746407B2 (ja) 2021-04-23 2025-09-30 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療

Also Published As

Publication number Publication date
JP2021167336A (ja) 2021-10-21
AU2018206851B2 (en) 2020-07-30
HK1209758A1 (en) 2016-04-08
JP7123225B2 (ja) 2022-08-22
KR102185237B1 (ko) 2020-12-02
KR102320059B1 (ko) 2021-11-01
JP2019112429A (ja) 2019-07-11
AU2020204613B2 (en) 2021-10-07
AU2013274389A1 (en) 2015-01-22
KR20200133395A (ko) 2020-11-27
KR20210130270A (ko) 2021-10-29
JP2018065845A (ja) 2018-04-26
CA2876636A1 (en) 2013-12-19
AU2020204613A1 (en) 2020-07-30
AU2018206851A1 (en) 2018-08-09
EP2861621A1 (en) 2015-04-22
KR20150035825A (ko) 2015-04-07
CN104603152A (zh) 2015-05-06
CN108310375A (zh) 2018-07-24
US20150158949A1 (en) 2015-06-11
AU2018206851C1 (en) 2021-11-25
CA2876636C (en) 2022-09-13
KR102185237B9 (ko) 2021-08-06
CN111494624A (zh) 2020-08-07
US9493570B2 (en) 2016-11-15
JP2021042208A (ja) 2021-03-18
EP2861621A4 (en) 2016-01-20
WO2013188494A1 (en) 2013-12-19
JP6814238B2 (ja) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7123225B2 (ja) 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
KR101532797B1 (ko) 인터페론 알파 유도성 약력학적 마커
JP2018535394A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
CA2686861A1 (en) Interferon alpha-induced pharmacodynamic markers
JP2015504430A (ja) Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
EP2714080A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
KR20180096633A (ko) Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
TW202229334A (zh) CD1a抗體及其用途
AU2020222262B2 (en) Type I interferon-mediated disorders
HK40034632A (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170801